Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

References

• JankuFStewartDJKurzrockRTargeted therapy in non-small-cell lung cancer: is it becoming a reality?Nat Rev Clin Oncol20107740141420551945
   PubMed Web of Science ®Google Scholar
• NormannoNDe LucaABiancoCEpidermal growth factor receptor (EGFR) signaling in cancerGene200636621616377102
   PubMed Web of Science ®Google Scholar
• De LucaANormannoNPredictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancerCurr Drug Targets201011785186420388064
   PubMed Web of Science ®Google Scholar
• NormannoNBiancoCDe LucaATarget-based agents against ErbB receptors and their ligands: a novel approach to cancer treatmentEndocr Relat Cancer200310112112653668
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet200536694961527153716257339
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A200410136133061331115329413
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
   PubMed Web of Science ®Google Scholar
• LinardouHDahabrehIJBafaloukosDSomatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLCNat Rev Clin Oncol20096635236619483740
   PubMed Web of Science ®Google Scholar
• SequistLVBellDWLynchTJHaberDAMolecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancerJ Clin Oncol200725558759517290067
   PubMed Web of Science ®Google Scholar
• SharmaSVBellDWSettlemanJHaberDAEpidermal growth factor receptor mutations in lung cancerNat Rev Cancer20077316918117318210
   PubMed Web of Science ®Google Scholar
• PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer2010101176077420966921
   PubMed Web of Science ®Google Scholar
• GazdarAFActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene200928Suppl 1S24S3119680293
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
   PubMed Web of Science ®Google Scholar
• JiHLiDChenLThe impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapiesCancer Cell20069648549516730237
   PubMed Web of Science ®Google Scholar
• FukuokaMYanoSGiacconeGMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]J Clin Oncol200321122237224612748244
   PubMed Web of Science ®Google Scholar
• KrisMGNataleRBHerbstRSEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA2003290162149215814570950
   PubMed Web of Science ®Google Scholar
• GiacconeGHerbstRSManegoldCGefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1J Clin Oncol200422577778414990632
   PubMed Web of Science ®Google Scholar
• HerbstRSGiacconeGSchillerJHGefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2J Clin Oncol200422578579414990633
   PubMed Web of Science ®Google Scholar
• KimESHirshVMokTGefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialLancet200837296521809181819027483
   PubMed Web of Science ®Google Scholar
• JännePAGurubhagavatulaSYeapBYOutcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access studyLung Cancer200444222115084387
   PubMed Web of Science ®Google Scholar
• MillerVAKrisMGShahNBronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancerJ Clin Oncol20042261103110915020612
   PubMed Web of Science ®Google Scholar
• DouillardJYShepherdFAHirshVMolecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trialJ Clin Oncol201028574475220038723
   PubMed Web of Science ®Google Scholar
• SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol200826152442244918458038
   PubMed Web of Science ®Google Scholar
• AsahinaHYamazakiKKinoshitaIA phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutationsBr J Cancer2006958998100417047648
   PubMed Web of Science ®Google Scholar
• InoueASuzukiTFukuharaTProspective phase II study of gefitinib for chemotherapy-naive patients with advanced non- small-cell lung cancer with epidermal growth factor receptor gene mutationsJ Clin Oncol200624213340334616785471
   PubMed Web of Science ®Google Scholar
• InoueAKobayashiKUsuiKFirst-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapyJ Clin Oncol20092791394140019224850
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
   PubMed Web of Science ®Google Scholar
• YangCHFukuokaMMokTSFinal overall survival results from a phase III, randomised, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS)Presented at European Society of Medical Oncology Meeting2010 (Abstract LBA2).
   Google Scholar
• LeeJSParkKKimSWA randomized phase III study of gefitinib (IRESSA) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lungPresented at: World Conference on Lung Cancer2009 (Abstract PRS4).
   Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol201011212112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med2010362252380238820573926
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGASridharaRFDA drug approval summary: gefitinib (ZD1839) (Iressa) tabletsOncologist20038430330612897327
   PubMed Web of Science ®Google Scholar
• AndoMOkamotoIYamamotoNPredictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinibJ Clin Oncol200624162549255616735708
   PubMed Web of Science ®Google Scholar
• KudohSKatoHNishiwakiYInterstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control studyAm J Respir Crit Care Med2008177121348135718337594
   PubMed Web of Science ®Google Scholar
• CellaDFBonomiAELloydSRReliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrumentLung Cancer19951231992207655830
   PubMed Web of Science ®Google Scholar
• NormannoNDe LucaAAldinucciDGefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasisEndocr Relat Cancer200512247148215947117
   PubMed Web of Science ®Google Scholar
• ZampaGMoscatoMBranniganBWProlonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinibLung Cancer200860345245418079016
   PubMed Web of Science ®Google Scholar
• PluquetECadranelJLegendreAOsteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survivalJ Thorac Oncol20105449149620195171
   PubMed Web of Science ®Google Scholar
• GarfieldDNormannoNOsteoblastosis and activating epidermal growth factor receptor mutations: a relationship?J Thorac Oncol20105441541620357615
   PubMed Web of Science ®Google Scholar
• MarchettiAFelicioniLButtittaFAssessing EGFR mutationsN Engl J Med20063545526528 author reply52652816452569
   PubMed Web of Science ®Google Scholar
• MarchettiANormannoNPintoCRecommendations for mutational analysis of EGFR in lung carcinomaPathologica2010102311912621171518
   PubMedGoogle Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med2008359436637718596266
   PubMed Web of Science ®Google Scholar
• Godin-HeymannNBryantIRiveraMNOncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationCancer Res200767157319732617671201
   PubMed Web of Science ®Google Scholar
• TurkeABZejnullahuKWuYLPreexistence and clonal selection of MET amplification in EGFR mutant NSCLCCancer Cell2010171778820129249
   PubMed Web of Science ®Google Scholar